Subscribe To
MKGAF / Merck KGaA says MS drug has blockbuster potential; key data expected in December
MKGAF News
By Reuters
October 30, 2023
Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui
Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an more_horizontal
By Reuters
October 19, 2023
Merck KGaA says MS drug has blockbuster potential; key data expected in December
The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that more_horizontal
By Reuters
October 19, 2023
Merck KGaA raises prospect of return to sales growth next year
Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its spe more_horizontal
By Seeking Alpha
August 13, 2023
Merck KGaA: Expect A 10% CAGR EBITDA Increase In 2024-2025
Merck KGaA reported disappointing Q2 results with a decrease in gross profit and EBIT compared to the previous year. The company remains confident in more_horizontal
By Seeking Alpha
August 5, 2023
Merck KGaA (MKGAF) Q2 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations more_horizontal